Most GLP-1 guidance assumes a constant body. Yours is not. The luteal phase, the two weeks before your period, slows gastric emptying, raises water retention, and amplifies nausea on the same dose that felt fine in the follicular phase. The pattern is well-documented in the gastric physiology literature, and easy to feel: month three on a GLP-1 can feel like four different medications.
Steady tracks your cycle as a data layer, not a calendar. You enter your last period date and your typical cycle length. The home screen shows the phase you're in alongside the day count. The coach knows. The symptom heatmap is colour-coded by phase, so a Tuesday of nausea in week four looks different from a Tuesday of nausea in week two.
For women on tirzepatide (Mounjaro, Zepbound), Steady also surfaces the contraception interaction at the moments it matters, after the first dose and after every dose escalation, based on the Eli Lilly label. The drug affects oral contraceptive absorption in ways most prescribers have not been trained to talk about. Steady has the conversation, calmly, at the right moment.
Built around how this medication actually works.
Phase next to dose
Home-screen card shows phase + day count + GLP-1 phase-specific advice.
Period and bleeding logging
Start, end, bleeding level, and cycle-specific symptoms, cramps, cravings, mood, energy.
Fertility-aware messaging
During the fertile window, the coach acknowledges it, without being heavy-handed.
Contraception interactions
Tirzepatide can reduce oral contraceptive effectiveness. Steady surfaces the four-week window after every dose change.
What the studies actually say.
Evidence-based summaries of the papers that informed every part of this page. Each article cites its sources.
Your cycle and your GLP-1: why month three feels like four different medications
Gastric emptying, appetite, and water retention shift across the menstrual cycle, and GLP-1s stack on top. A phase-by-phase guide.
GLP-1s and the pill: a warning women on Mounjaro and Zepbound need to read
Tirzepatide can reduce the effectiveness of oral contraceptives. The label is clear about it; the conversation often isn't. Here is what to know, what to switch to, and for how…
GLP-1s and PCOS: what the early evidence shows for women with insulin resistance
Polycystic ovary syndrome and GLP-1 weight loss interact in ways that are still being studied. Here is what the small but growing literature shows about cycles, fertility, and…
GLP-1s in perimenopause: why the same dose hits different
The years before menopause change body composition, insulin sensitivity, and how a GLP-1 feels. Here is what shifts, and the small adjustments that make the medication work with…
GLP-1s and pregnancy: the two-month wash-out you need to plan for
GLP-1s are not approved for use in pregnancy. The standard guidance is to stop the medication two months before trying to conceive. Here is the reasoning, the gap in the data, and…
GLP-1s and fertility: the 'Ozempic baby' surprise, and the contraception catch no one mentions
Women on GLP-1s are reporting unexpected pregnancies, sometimes after years of trying. The reason is real biology, and it comes with a contraception warning that too few are told.…
Cycle-aware GLP-1 tracking, so you stop blaming yourself for biology. Free on the App Store.
Built around how your body actually works on Ozempic, Wegovy, Mounjaro and Zepbound. iPhone only, for now.